

<b>7</b>	<b>GENERAL INTRODUCTION, AIM &amp; OUTLINE OF THE THESIS</b>
<b>14</b>	<b>CHAPTER 1</b> Body Fluid Biomarkers in Parkinson's Disease. <i>Submitted to Nature Reviews Neurology</i>
<b>35</b>	<b>CHAPTER 2</b> Generation and Characterization of Novel Conformation-Specific Monoclonal Antibodies for A-Synuclein Pathology. <i>Neurobiology of Disease</i>
<b>75</b>	<b>CHAPTER 3</b> Oligomeric and Phosphorylated Alpha-Synuclein as Potential CSF Biomarkers for Parkinson's Disease. <i>Molecular Neurodegeneration</i>
<b>101</b>	<b>CHAPTER 4</b> Longitudinal Changes in CSF Alpha-Synuclein Species Reflect Parkinson's Disease Progression. <i>Movement Disorders</i>
<b>116</b>	<b>CHAPTER 5</b> Increased Levels of CSF Total but Not Oligomeric or Phosphorylated Forms of Alpha- Synuclein in Patients Diagnosed with Probable Alzheimer's Disease. <i>Scientific Reports</i>
<b>129</b>	<b>CHAPTER 6</b> CSF Oligomeric Alpha-Synuclein Levels as a Preclinical Marker of Parkinson's Disease: A Study in LRRK2 Mutation Carriers and Sporadic Parkinson's Disease Cases. <i>Submitted to Neurology</i>
<b>149</b>	<b>CHAPTER 7</b> Summary & General Discussion
<b>161</b>	<b>APPENDIX</b> List of Publications Word of Thanks About the Author